Use access key #2 to skip to page content.
$0.22 -0.01 (-4.35%)
8/29/2008 3:41 PM

Cambridge Heart, Inc. (CAMH.OB)

CAPS Rating:
*

The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

CAMH.OB doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

23 Outperforms
24 Underperforms
 

All-Stars

7 Outperforms
17 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on CAMH.OB are also bullish on:

Members bearish on CAMH.OB are also bearish on:

Ticker Tags

Medical Appliances & Equipment (106), Medical Diagnostic Equipment (10), Micro Cap (4824)
Suggest a tag

Cambridge Heart, Inc. At A Glance

Current Price: $0.22
Last Trade Time: 8/29/2008 3:41 PM
Open: $0.23
Previous Close: $0.23
Daily Range: $0.21 - $0.23
52-Week Range: $0.21 - $3.90
Volume: 136,630
Market Cap: $14.89M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CAMH.OB VS S&P 500 (SPY)

CAMH.OB 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for CAMH.OB.

Top Bull Pitch

Recs

1

Cambridge Heart, Inc. (CAMH.OB)

Avatar paulmacdo (< 20) Submitted: 4/28/07 11:58 AM

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sa...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

5

Cambridge Heart, Inc. (CAMH.OB)

Avatar JMacAttack (99.64) Submitted: 3/05/07 4:36 PM

The company is losing money hand over fist, and the insiders are selling off like the ship is sinking fast. The CFO and several other insiders have sold 100% of their holdings - not a good sign.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 11 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (CAMH.OB)

Avatar dayrider (89.89) Submitted: 11/16/07 9:10 PM : Outperform Start Price: $1.53 CAMH.OB Score: -74.27

Sales growing
Losses shrinking
Market overreaction to a difficult to understand study that likely won't change doctor's practice patterns
BUY!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CAMH.OB)

Avatar WindRules (< 20) Submitted: 6/15/07 5:56 PM : Outperform Start Price: $4.43 CAMH.OB Score: -79.00

Good product.
Numbers: -.16 this year, projected +.13 next year
PE from -28.26 to +33.69.
marketwatch
Their site: Increase in revenue from first quarter 2006 to first quarter 2007: 83%

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (CAMH.OB)

Avatar paulmacdo (< 20) Submitted: 4/28/07 11:58 AM : Outperform Start Price: $3.36 CAMH.OB Score: -79.52

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CAMH.OB)

Avatar aircarp (< 20) Submitted: 3/30/07 10:26 PM : Outperform Start Price: $3.18 CAMH.OB Score: -83.68

MTWA test now mandatory for Medicare and half of US insured prior to implant of an ICD.

New Sales and Marketing relationship with St. Jude (STJ). 2000 experienced and connected sales professionals will soon be selling the product.

FDA Approved. Patent Holder with mo Competition.

$120M+ Revenue target with 50-65% Margin = $25+ stock over next 2 years.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (CAMH.OB)

Avatar obiwankenobe1250 (81.65) Submitted: 3/22/07 3:20 PM : Outperform Start Price: $3.23 CAMH.OB Score: -83.16

Like the news...

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 11 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackSnow 95.97 12/31/07 Outperform NS $1.01-78.22%-11.91%-66.30 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners